Who to call at PHARMACYTE BIOTECH, INC., and when
Fundz watches for the moments PHARMACYTE BIOTECH, INC. starts buying, and tells you who to reach.
- An alert the day PHARMACYTE BIOTECH, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at PHARMACYTE BIOTECH, INC., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at PHARMACYTE BIOTECH, INC.. With Fundz connected, it knows.
PHARMACYTE BIOTECH, INC.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
pharmacytebiotech.comAI Executive Summary
AI-powered analysis of 8-K filing content
PharmaCyte stockholders approved an amendment to the 2022 Equity Incentive Plan adding 2,250,000 shares for awards, and approved issuing common stock underlying convertible preferred stock and warrants from an August 17, 2025 securities purchase agreement, at a special meeting held October 30, 2025. The approvals expand equity compensation capacity and authorize potential dilution from the financing.
Key Takeaways
Stockholders approved adding 2,250,000 shares to the 2022 Equity Incentive Plan, expanding the pool available for stock-based awards.
Stockholders approved Proposal 1 under Nasdaq Listing Rule 5635(d), authorizing issuance of common stock underlying convertible preferred stock and warrants issued under the August 17, 2025 Securities
3 more takeaways
Related Filings (2)
2 more filings from PHARMACYTE BIOTECH, INC. in the last 90 days
Filing Overview
What This Means
PHARMACYTE BIOTECH, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.